We are live on ! Find out more
ARTL icon

Artelo Biosciences
ARTL

3 hedge funds and large institutions have $43K invested in Artelo Biosciences in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding

Funds holding: 1 → 3 (+2)

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

0% less ownership

Funds ownership: 0% → 0% (-0%)

77% less capital invested

Capital invested by funds: $189K → $43K (-$146K)

Holders
3
Holders Change
+2
Holders Change %
+200%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$44.2K
2
UBS Group
UBS Group
Switzerland
+$9.91K
3
TRCT
Tower Research Capital (TRC)
New York
+$762

Top Sellers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
-$189K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
1
Goldman Sachs
New York
$34K +$44.2K +58 New
UBS Group
2
UBS Group
Switzerland
$8K +$9.91K +13 New
TRCT
3
Tower Research Capital (TRC)
New York
$1K +$762 +1 New
CH
4
CVI Holdings
Delaware
– -$189K -152 Closed

ARTL Hedge Fund Activity: Q3 2019 in Review

3 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q3 2019, worth a combined $43K — down 77% from $189K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ARTL positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $44.2K. The largest seller was CVI Holdings, exiting entirely with an estimated $189K sold.

  • 3 institutional investors held Artelo Biosciences (ARTL) as of Q3 2019, up from 1 in Q2 2019.
  • Funds reported $43K of Artelo Biosciences stock for Q3 2019, down 77% quarter-over-quarter.
  • 3 funds opened new Artelo Biosciences positions in Q3 2019 and 1 closed out, a net change of +2 holders.
  • The largest Artelo Biosciences buyer in Q3 2019 was Goldman Sachs, an estimated $44.2K added.
  • The largest Artelo Biosciences seller in Q3 2019 was CVI Holdings, an estimated $189K sold.

Based on aggregated 13F filings for Q3 2019.